Aastrom Biosciences to Present at the 2013 Therapeutic Area Partnerships Conference
November 12 2013 - 9:00AM
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of
patient-specific expanded multicellular therapies for the treatment
of severe chronic cardiovascular diseases, today announced that
Nick Colangelo, President and CEO of Aastrom, will present at the
2013 Therapeutic Area Partnerships Conference on Tuesday, November
19 at 4:30 p.m. EST at the Hyatt Regency in Boston, MA. The
conference organizers have selected ixmyelocel-T as a Top Project
to Watch in advanced therapies.
A copy of the presentation will be available on the company's
website at http://investors.aastrom.com/events.cfm.
Organized by Elsevier Business Intelligence, the 2013
Therapeutic Area Partnerships (TAP) is a three-day conference aimed
at bringing together decision makers in the biopharmaceutical
industry to assess the most promising drug programs available for
partnering in oncology, cardiovascular/metabolic disease,
neuroscience, infectious diseases, anti-inflammatory/autoimmune
diseases, as well as advanced cellular and gene therapies.
About Aastrom Biosciences
Aastrom Biosciences is the leader in developing
patient-specific, expanded multicellular therapies for use in the
treatment of patients with severe, chronic cardiovascular
diseases. The company's proprietary cell-processing technology
enables the manufacture of ixmyelocel-T, a patient-specific
multicellular therapy expanded from a patient's own bone marrow and
delivered directly to damaged tissues. Aastrom has advanced
ixmyelocel-T into late-stage clinical development, including a
Phase 2b clinical trial in patients with advanced heart failure due
to ischemic dilated cardiomyopathy. For more information, please
visit Aastrom's website at www.aastrom.com.
The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
This document contains forward-looking statements,
including, without limitation, statements concerning clinical trial
plans and progress, objectives and expectations, clinical activity
timing, intended product development, the performance and
contribution of certain individuals and expected timing of
collecting and analyzing treatment data, all of which involve
certain risks and uncertainties. These statements are often, but
are not always, made through the use of words or phrases such as
"anticipates," "intends," "estimates," "plans," "expects," "we
believe," "we intend," and similar words or phrases, or future or
conditional verbs such as "will," "would," "should," "potential,"
"could," "may," or similar expressions. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the inherent uncertainties associated with the
closing of the offering described herein, Aastrom's intended use of
proceeds in connection with the offering, clinical trial and
product development activities, regulatory approval requirements,
competitive developments, and the availability of resources and the
allocation of resources among different potential uses. These and
other significant factors are discussed in greater detail in
Aastrom's Registration Statement on Form S-1 described above,
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and
other filings with the Securities and Exchange Commission. These
forward-looking statements reflect management's current views and
Aastrom does not undertake to update any of these forward-looking
statements to reflect a change in its views or events or
circumstances that occur after the date of this release except as
required by law.
CONTACT: Media contact:
Andrea Coan
Berry & Company
acoan@berrypr.com
(212) 253-8881
Investor contact:
Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Sep 2023 to Sep 2024